Numerous investigators within the current P30 application have indicated a need for 1) primary human airway epithelial cells (from lung transplantation) or nasal epithelial cells from CF and non-CF individuals;2) measurements of the functional anatomy of respiratory epithelia that track airway surface liquid homeostasis, ciliary beating, and mucociliary transport;or 3) CFTR bioelectric assays in human subjects. Core C is intended to provide the necessary expertise and supply these reagents in a centralized, standard format. The Core will facilitate transition from in vitro proof of concept studies to in vivo analysis, and furnish expertise in cell culture, airway physiology, and human translational science.
The specific aims of Core C are:
Specific Aim 1 : To procure, grow, and distribute well-differentiated primary human airway epithelial cells from CF and non-CF donors. The Core will interface with human subjects to (1) procure, derive, and grow cells from lung transplants, nasal polypectomies, or nasal brushings;(2) maintain a robust informatics system that includes clinical information regarding consenting subjects, CFTR genotyping, performance of cells in culture, and a large repository of frozen cells for the P30 Center;and (3) provide quality assurance and regulatory expertise necessary to protect the rights and safety of human subjects, including IRB submissions, material transfer agreements, and HIPAA compliance.
Specific Aim 2 : To conduct functional anatomic imaging of airway epithelia by 1-micron resolution Spectral Domain-Optical Coherence Tomography (?mu?OCT) in vitro and ex vivo. The Core will conduct ?mu?OCT imaging of the functional anatomy of respiratory epithelia in (1) fully-differentiated primary epithelial cells (of human or non-human origin);and (2) intact full-thickness tracheas from animal (e.g. pig, ferret, rat) or human origin.
Specific Aim 3 : To support the design and conduct in vivo measurements of CFTR activity in human subjects. The Core will provide expertise in the conduct of NPD measurements, assist in the development of new in vivo assays of CFTR activity (e.g intestinal current measurements), and provide data management, biostatistical, and regulatory expertise to assist in the design, conduct, and interpretation of CF clinical trials utilizing these in vivo capabilities. As such, Core C is poised to "bridge the gap" between in vitro proof of concept studies, new clinical insight regarding disease mechanisms, and clinical translation of novel CF therapeutics.

Public Health Relevance

(See Instructions):

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK072482-07
Application #
8451291
Study Section
Special Emphasis Panel (ZDK1-GRB-7)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
7
Fiscal Year
2013
Total Cost
$180,987
Indirect Cost
$52,882
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Heltshe, Sonya L; Rowe, Steven M; Mayer-Hamblett, Nicole (2014) Evaluating the predictive ability of sweat chloride. J Cyst Fibros 13:118
Hill, Aubrey E; Plyler, Zackery E; Tiwari, Hemant et al. (2014) Longevity and plasticity of CFTR provide an argument for noncanonical SNP organization in hominid DNA. PLoS One 9:e109186
Dean, Nichole; Ranganath, Neel K; Jones, Brandon et al. (2014) Porcine nasal epithelial cultures for studies of cystic fibrosis sinusitis. Int Forum Allergy Rhinol 4:565-70
Lee, Seakwoo; Henderson, Mark J; Schiffhauer, Eric et al. (2014) Interference with ubiquitination in CFTR modifies stability of core glycosylated and cell surface pools. Mol Cell Biol 34:2554-65
Oren, Yifat S; McClure, Michelle L; Rowe, Steven M et al. (2014) The unfolded protein response affects readthrough of premature termination codons. EMBO Mol Med 6:685-701
Xue, Xiaojiao; Mutyam, Venkateshwar; Tang, Liping et al. (2014) Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. Am J Respir Cell Mol Biol 50:805-16
McClure, Michelle L; Wen, Hui; Fortenberry, James et al. (2014) S-palmitoylation regulates biogenesis of core glycosylated wild-type and F508del CFTR in a post-ER compartment. Biochem J 459:417-25
Zhang, Shaoyan; Ranganath, Neel K; Skinner, Daniel et al. (2014) Marked repression of CFTR mRNA in the transgenic Cftr(tm1kth) mouse model. J Cyst Fibros 13:351-2
Boyle, Michael P; Bell, Scott C; Konstan, Michael W et al. (2014) A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2:527-38
Tuggle, Katherine L; Birket, Susan E; Cui, Xiaoxia et al. (2014) Characterization of defects in ion transport and tissue development in cystic fibrosis transmembrane conductance regulator (CFTR)-knockout rats. PLoS One 9:e91253

Showing the most recent 10 out of 50 publications